Company: EHC
Filing Date: 2025-06-03
Form Type: 8-K
Source: 0000785161-25-000028
Chunk: 0

Company: Encompass Health Corp
Filing Date: 2025-06-03
Form: 8-K
Item: Item 7.01
Chunk 0
---
ITEM 7.01.

Regulation FD Disclosure.

Members of Encompass Health Corporation’s (the “ Company” or “ Encompass Health”) senior management team are scheduled to meet with investors and analysts at various meetings on June 4, 2025 and June 18, 2025.

The Company reiterates as of the date hereof its guidance previously reported in the Current Report on Form 8-K, dated April 24, 2025, and during the Company's earnings conference call held on April 25, 2025. Accordingly, the Company continues to expect the following full-year 2025 ranges:

• Net operating revenue of $5,850 million to $5,925 million;

•Adjusted EBITDA of $1,185 million to $1,220 million; and

• Adjusted earnings per share from continuing operations attributable to Encompass Health of $4.85 to $5.10.

The information contained herein is being furnished pursuant to Item 7.01 of Form 8-K, “ Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein.

Note Regarding Presentation of Non-GAAP Financial Measures

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees - accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company’s results computed in accordance with GAAP.

However, the following reasonably estimable GA